GET TOP RATED STOCK ALERTS ACTIVE TRADERS DEPEND ON
SIGN UP TODAY FOR FREE NEWS DRIVEN ALERTS
Backed by $1 million in funding from the CVS Health Foundation, the pilot initiative offers free, virtual health screenings to support aging with confidence, care, and convenience
- Health checks include assessments for heart health, memory, cognitive function, and mental health
- No travel required — all appointments are virtual and confidential
- Community Health Workers provide personalized follow-up support and connect patients to local resources
- The program is now available in New York City, with plans to expand throughout 2025
- Free for patients on Medicaid, covered by insurance for patients on Medicare
New York, NY – July 10, 2025 — Treatment.com AI Inc. (CSE: TRUE) (OTCQB: TREIF) (Frankfurt: 939) (“Treatment”) is pleased to announce that building off their successful graduation from AARPs AgeTech Accelerator, its subsidiary, Rocket Doctor Inc., has partnered with EngageWell IPA in a program funded by CVS Health (NYSE: CVS) Foundation to launch the Healthy Aging Program — a new pilot initiative offering virtual health screenings for adults aged 60 and older across New York City.
Funded through a 5-year, $1M grant from the CVS Health® Foundation, EngageWell and Rocket Doctor’s program is designed to support older adults in maintaining their health and independence. It offers confidential virtual assessments that screen for common health concerns related to aging, including heart health, memory and brain function, and mental well-being. Board-certified physicians conduct consultations via phone or video and develop personalized follow-up care plans. Community Health Workers are also available to help patients connect with the telehealth provider and with necessary follow-up care.
“Aging shouldn’t mean losing access to care, it should mean getting the support you need, wherever you are,” said Dr. William Cherniak, Founder and CEO of Rocket Doctor. “We’re proud to again partner with EngageWell to bring high-quality, proactive care directly into the homes of older adults across New York City. We’re equally thrilled that the CVS Health Foundation is funding EngageWell to implement this important program.”
Participants who complete their screenings receive valuable health information, a physician consultation, and can receive up to $45 in gift cards. No insurance is required for patients on Medicaid, and is accepted for patients on Medicare. The entire process is designed to be simple, supportive, and stress-free.
“Too often, older adults who face language barriers, low health or digital literacy, or systemic inequities are left to navigate fragmented healthcare systems on their own,” said Christopher Joseph, Executive Director of EngageWell IPA. “Through the Healthy Aging Program, we’re not just delivering services – we’re building a care model rooted in dignity, cultural relevance, and trust. By combining community-based outreach with user-friendly technology, we’re bridging gaps and creating lasting pathways to better health for aging New Yorkers.”
The program is now live and being offered in partnership with community-based organizations and care navigators throughout New York City. By combining technology, human connection, and wrap-around support, the Healthy Aging Program helps ensure older adults stay healthy, informed, and in control of their care, without ever needing to leave home.
About Rocket Doctor Inc.
Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality comprehensive care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like.
Visit www.rocketdoctor.io or contact media@rocketdoctor.io.
About EngageWell IPA
EngageWell IPA is a leading healthcare organization created in 2016 by New York City not-for-profit organizations working together to offer coordinated, integrated treatment options that include addressing social determinants of health — housing, nutrition, economic security. Through innovative clinical care models and strategic partnerships, EngageWell strives to create a more equitable healthcare system that addresses health disparities and breaks the links between poverty, structural racism, and poor health. www.engagewellipa.com or contact christopher@engagewellipa.com.
About Treatment.com AI
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at: www.treatment.com or contact info@treatment.com.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO – Treatment.com AI Inc.
Email: ehamza@treatment.com
Media inquiries: media@rocketdoctor.io
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com AI believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Source: Treatment.com AI Inc.
Vancouver, BC – June 20, 2025 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) announces that it has granted 799,920 restricted share units (“ RSUs ”) and 162,480 stock options (“ Options ”) to officers, directors, consultants and employees of the Company.
The Options are each exercisable for one common share of the Company at an exercise price of C$0.50 per share for a period of three years from the grant date and vest over a one-year term. 700,000 RSUs are valid for a term of five years and 99,920 RSUs are valid for a term of three years. All RSUs vest over a period of one year from the grant date. All Options and RSUs are subject to the terms of the Company’s equity plans and applicable securities law hold periods.
Further, the Company announces that it has engaged FN Media Group, LLC (FN Media”) to commence a news/media marketing campaign for a one (1) day term during the week of June 23 – June 27, 2025, in consideration of USD$4,295.
FN Media shall utilize its proprietary traffic generation application and Google/Yahoo Digital media ads platforms. FN Media does not currently own any interest, directly or indirectly, in the Company or its securities. FN Media’s address is 49 N. Federal Hwy, #281, Pompano Beach, Florida, USA, 33062 (phone: (954) 345-0611, email: patrick@financialnewsmedia.com ). FN Media and its directors and officers are arm’s length from the Company.
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at www.treatment.com or contact info@treatment.com .
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
Email: ehamza@treatment.com
Media inquiries: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Source: Treatment.com AI Inc.
Sign Up for FREE
Stock Alerts from
to be the first to know when this emerging company issues Breaking News!
About Treatment.com AI Inc.
Treatment.com AI Re-Imagining Access to Primary Healthcare
Disclaimer
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty two hundred dollars for Treatment.com AI Inc. current news coverage by the company. FNMG HOLDS NO SHARES OF Treatment.com AI Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.